AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04277312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nourish
Description: The Nourish intervention is a school food environment intervention which included weekly healthy snack provision supplied by food industry partners, enhancement of canteen dining area (café style, tablecloths, centre pieces, bunting and menu boards, healthy eating posters), attendance at Tasting Days held in Higher Education Colleges (children were encouraged to try new foods provided by industry partners and received stamps on 'food passports' in return) and sensory educational and cookery activities.
Study NCT03580382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-3379 (ERBB3 antibody)
Description: 15mg/kg IV Q3W
Study NCT02702050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation (LPG system; Cellu M6 Integral I)
Description: For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
Study NCT02702050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
Study NCT00601744 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio-Taped Interview
Description: Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration.
Study NCT03451240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corporate Athlete® Resilience
Description: The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~1. Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~2. Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work.
Study NCT00601744 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: 5-10 minute questionnaire to be completed after the interview.
Study NCT03497026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Bronchoscopy Platform
Description: Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
Study NCT02155764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octacalcium phosphate
Description: Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
Study NCT02155764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss
Description: Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
Study NCT02155764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tricalcium phosphate
Description: Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
Study NCT03986775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: isomaltulose
Description: replacement of sucrose with low-glycemic isomaltulose
Study NCT03986775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: conventional beverage with sucrose
Study NCT00798655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight
Study NCT00798655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
Study NCT00798655 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day.
Study NCT02698618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic
Description: Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured.
Study NCT02698618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic
Description: Pre-PCI and treatment:~1. At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~2. At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured.
Study NCT02698618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomization
Description: Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
Study NCT02698618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Randomization
Description: Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence \[Body Mass Index (BMI) ≥30 kg/m2\] with the implementation of a dedicated randomization list.
Study NCT02698618 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: 1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR).
Study NCT02698618 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: 1. Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~2. PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~3. Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR).
Study NCT00960934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
Study NCT00960934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched oral placebo to MK-5442
Study NCT00960934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched oral placebo to MK-5442
Study NCT00960934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, two 400 IU tablets daily throughout the study.
Study NCT00960934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, two 400 IU tablets daily throughout the study.
Study NCT00960934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
Study NCT00960934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
Study NCT04317352 — intervention group
Intervention type: PROCEDURE
Intervention: MVR
Description: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
Study NCT02765633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor
Study NCT01679093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
Study NCT01679093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol
Description: droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
Study NCT01679093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexametasone: 4 mg intravenous administration after the induction of anesthesia.
Study NCT00731263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8055
Description: Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Study NCT02363270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV Push or or IV Drip
Study NCT00442013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
Study NCT00442013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
Study NCT02156960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab treatment in osteoporotic patients
Description: To examine the effectiveness of denosumab in osteoporotic patients
Study NCT02156960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide treatment in osteoporotic patients
Description: To examine the effectiveness of teriparatide in osteoporotic patients
Study NCT02156960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab and teriparatide treatment in osteoporotic patients
Description: To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
Study NCT02025491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
Study NCT01870219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
Study NCT01870219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine was given to 1mg/kg ıv bolus
Study NCT02395497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal Antibody (Humanized Anti-CD52)
Study NCT02395497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02395497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Penile Allotransplantation
Study NCT04624035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Collamer Lens (ICL) in treatment of myopia in adults.
Description: ICL Group: After mydriatic eye drops and topical anesthesia instillation, a 3-mm temporal corneal incision was done. Viscoelastic material was injected in the anterior chamber (AC). An injector cartridge (STAAR Surgical) was used to insert the ICL V4c model with central hole). The four footplates of the ICL were positioned on the ciliary sulcus at the 180° axis. Viscoelastic material was entirely taken away.
Study NCT04624035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Intraocular Lens (IPCL) in treatment of myopia in adults.
Description: IPCL Group: Topical anesthetic and mydriatic agents were instilled before surgery. Using peripulbar anaesthesia, the IPCL (V2 model with central hole) was implanted into the AC through a 3 mm clear corneal incision after viscoelastic material injection. The footplates were subsequently tucked behind the iris, followed by a thorough viscoelastic removal.
Study NCT03919864 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONTROL Group
Description: Participants will receive a generic printed list of hospital, community, and national supportive care resources.
Study NCT04045977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
Study NCT04045977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
Study NCT04045977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapeutic support
Description: 8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work.
Study NCT04045977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapeutic support
Description: 8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
Study NCT00598208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corifollitropin alfa
Description: On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
Study NCT00598208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection
Description: Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
Study NCT02350842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: triple-site biventricular pacing with peri-operative echo guidance
Description: placement of the third lead by peri-operative echo guidance.
Study NCT02350842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard biventricular pacing
Description: standard biventricular pacing without optimization by echo guidance
Study NCT04832048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercise
Description: The physical training program was carried out 3 days a week in 1-hour sessions focused on basic endurance exercises (global body activities), strength (specific muscle region activities) and flexibility.~Intensity was be determined by Maximum Heart Rate (HRF).
Study NCT04832048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No physical exercise
Description: No programmed physical exercise
Study NCT03380520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Ferric carboxymaltose will be administered according to product specification dosing
Study NCT03380520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV nacl 0.9%
Study NCT04523610 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telehealth phone calls
Description: The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
Study NCT04523610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth phone calls
Description: The volunteer-based weekly Telehealth support primarily provides program users with friendly listening/conversation. Volunteers will also inquire about their general wellbeing, provide information about COVID-19, and ask if the older adult needs any help or support (e.g. food delivery, medication from their pharmacy).
Study NCT04523610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Volunteer of TIP-OA Program
Description: Participant is a volunteer of the TIP-OA Program